Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.
Back
ADCs Advances: Transforming Breast Cancer Care Today and Beyond
This OncLive News Network series examines the expanding role of antibody drug conjugates (ADCs) in the treatment of breast cancer. Experts Paolo Tarantino, MD and Jason Aboudi Mouabbi, MD review key data from ESMO 2025 and describe how ADCs are influencing care across HER2 positive, HER2 low, hormone receptor positive, and triple negative disease. The faculty outline major findings from DESTINY Breast05, DESTINY Breast11, TROPION Breast02, and ASCENT03, emphasizing how trastuzumab deruxtecan, datopotamab deruxtecan, and sacituzumab govitecan are moving into both early and metastatic settings. The discussion highlights clinical considerations such as patient selection, biomarkers, and the influence of brain involvement or early relapse on treatment choice. The experts review safety profiles, supportive care needs, and practical issues related to infusion planning and monitoring. The series concludes with emerging strategies that include combination therapy, next generation targets, and research priorities that will shape future use of ADCs in breast cancer.
ADCs Advances: Transforming Breast Cancer Care Today and Beyond
Episodes
All
All
Discover how novel antibody-drug conjugates effectively target brain metastases, offering hope for reducing CNS recurrences in cancer patients.
A new drug shows promise in treating triple-negative breast cancer, significantly improving survival rates and offering hope for better treatment options.
Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.
EP. 5: Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer
Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.
Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.
Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.
Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.
Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5